Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights
HOPKINTON, Mass., March 31 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) today reported consolidated financial results for the year ended December 31, 2007 and company highlights.
"2007 was a year of significant clinical, regulatory, pipeline and business accomplishments that helped advance our mission of building a leading biopharmaceutical company focused on disorders of the central nervous system," commented Peter G. Savas, Chairman and Chief Executive Officer of Alseres. "Our progress reinforces our confidence in the broad potential of our pipeline and in our leadership in nerve repair and regenerative therapeutics. Our focus in 2008 will be on commencing the Phase IIb trial of CETHRIN, partnering our molecular imaging assets and closing collaborations for our regenerative therapeutics."
More: http://www.alseres.com/
0
Cethrin - Clinical Trial In Acute Spinal Cord Injury Results
Started by
Apparelyzed
, Apr 01 2008 04:26 PM
1 reply to this topic
Top#2
carole338
-
- Members
-
- 428 posts
Member
- Gender:Female
- Country:Bergen County, NJ
- Spinal Injury Level / Relationship:T11 L2 Incomplete ASIA C
- Injury Date:26-02-2007
Posted 02 April 2008 - 03:35 PM
This is a very interesting and promising article. I went into their site and printed out news articles, program and product information. Looks like I have a lot of reading ahead of me.
Carole
Carole
"It's only the giving that makes you what you are." Tull
1 user(s) are reading this topic
0 members, 1 guests, 0 anonymous users
